Search - tctmd.com

Displaying 21 - 40 of 84

Sort: Relevancy | Date

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Conference News TCT 2020

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

Michael O'Riordan

October 17, 2020

News Conference News TCT 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

Shelley Wood

October 16, 2020

News Conference News TCT 2020

MITHRAS: No Upside to Closing iASDs Caused by Transcatheter MV Interventions

Shelley Wood

October 15, 2020

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

Presentation TCT 2020

Combined Optical Coherence Tomography and Fractional Flow Reserve Assessment to Better Predict Adverse Event Outcomes in DM Patients: COMBINE (OCT–FFR) Trial

Presenter: Elvin Kedhi

October 14, 2020

News Conference News TCT 2020

OCT Proves Predictive in Diabetic Patients, Even in FFR-Negative Lesions

Shelley Wood

October 14, 2020

Presentation TCT 2020

TCT 281: Clinical Outcomes of Optical Coherence Tomography Detected High Risk Versus Low Risk Coronary Atherosclerotic Lesions in Medically Treated Fractional Flow Reserve Negative Lesions in Diabetes Mellitus Patients. The COMBINE Trial.

Presenter: Elvin Kedhi

October 14, 2020

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

News Conference News TCT 2019

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

Caitlin E. Cox

October 01, 2019

Presentation TCT 2019

The ABILITY DIABETES Global Trial: The Largest Randomized Control Trial With Coronary Stents for the Diabetic Population

Presenter: Antonio Colombo

September 28, 2019

Presentation TCT 2019

The ABILITY DIABETES GLOBAL Imaging Study (Randomized Control Trial Comparing Abluminus DES vs. Xience)

Presenter: Azeem Latib

September 28, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Two: COAPT Prompts Round of Applause, Plus New Valve Insights

Shelley Wood

September 23, 2018

Advertisement

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

MITHRAS: No Upside to Closing iASDs Caused by Transcatheter MV Interventions

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Combined Optical Coherence Tomography and Fractional Flow Reserve Assessment to Better Predict Adverse Event Outcomes in DM Patients: COMBINE (OCT–FFR) Trial

OCT Proves Predictive in Diabetic Patients, Even in FFR-Negative Lesions

TCT 281: Clinical Outcomes of Optical Coherence Tomography Detected High Risk Versus Low Risk Coronary Atherosclerotic Lesions in Medically Treated Fractional Flow Reserve Negative Lesions in Diabetes Mellitus Patients. The COMBINE Trial.

Predicting Final Valve Position After TAVR: Different Devices, Different Success

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

FORZA: For Intermediate Lesions, OCT-Guided PCI Costs More, Yields Better Outcomes vs FFR

The ABILITY DIABETES Global Trial: The Largest Randomized Control Trial With Coronary Stents for the Diabetic Population

The ABILITY DIABETES GLOBAL Imaging Study (Randomized Control Trial Comparing Abluminus DES vs. Xience)

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

TCT 2018, Day Two: COAPT Prompts Round of Applause, Plus New Valve Insights

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content